BioPlus Co. Ltd. (099430.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea

Price

3,215.00 KRW

Market cap

186.25 bn KRW

P/E (2025)

–

P/S (2025)

2.05

Dividend yield

2.18 %

Net margin

16.50 %

Return on equity (ROE)

–

Return on assets (ROA)

–

BioPlus Co. Ltd. financials

Fiscal year	2024	2025
Revenue	66.41 bn KRW	90.90 bn KRW
Gross profit	42.64 bn KRW	60.61 bn KRW
Operating income	23.67 bn KRW	15.01 bn KRW
EBIT	17.93 bn KRW	17.84 bn KRW
Net income	14.15 bn KRW	15.00 bn KRW

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BioPlus Co. Ltd.

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.